News & Updates
Filter by Specialty:
Full anticoagulation dosing confers survival advantage in hospitalized COVID-19 patients
A full, therapeutic dosing of anticoagulation flops for reducing the incidence of overall combined outcomes in noncritically ill patients hospitalized with COVID-19 as compared with prophylactic dosing, although there is a signal of benefit for mortality and disease progression with the therapeutic dosing, as shown in the FREEDOM COVID trial presented at ACC.23/WCC.
Full anticoagulation dosing confers survival advantage in hospitalized COVID-19 patients
23 Mar 2023
Neurologic disability predicts severe ED in men infected with HTLV-1
Patients with human T-lymphotropic virus 1 (HTLV-1) infection may develop erectile dysfunction (ED), and time to progression to its severe form is significantly associated with the degree of neurologic compromise at baseline, reveals a study.
Neurologic disability predicts severe ED in men infected with HTLV-1
21 Mar 2023
HCC risk in CHB patients persists 12 years after HBsAg loss
Patients with chronic hepatitis B (CHB) still have a non-negligible risk of hepatocellular carcinoma (HCC) 12 years after achieving hepatitis B surface antigen (HBsAg) seroclearance, especially if cirrhosis is present, a large territory-wide real-world study in Hong Kong has shown.
HCC risk in CHB patients persists 12 years after HBsAg loss
21 Mar 2023
Telbivudine use during pregnancy safe, effective in HBsAG-positive mothers
Use of telbivudine (LdT) during the second trimester of pregnancy helps prevent mother-to-child transmission of hepatitis B virus, reveals a study. In addition, treatment with LdT during pregnancy is safe in the long term for both mothers and infants.
Telbivudine use during pregnancy safe, effective in HBsAG-positive mothers
20 Mar 2023
Add-on amantadine of no help in hospitalized COVID-19 patients
The addition of amantadine to standard care falls short of improving the likelihood of recovery of patients hospitalized with COVID-19, according to a study.
Add-on amantadine of no help in hospitalized COVID-19 patients
20 Mar 2023
Novel meningitis/encephalitis CSF testing shortens antiviral prescribing duration
The duration of antiviral prescribing has become much shorter with the introduction of the Biofire Filmarray meningitis/encephalitis (M/E) panel, a study has shown. However, its influence on antibiotic prescribing or health services in a paediatric hospital is minimal.